Aktis Oncology (NASDAQ:AKTS) Coverage Initiated by Analysts at TD Cowen

TD Cowen initiated coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating on the technology company’s stock.

Separately, Wall Street Zen raised Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Aktis Oncology presently has a consensus rating of “Buy” and a consensus price target of $31.67.

Aktis Oncology Price Performance

NASDAQ:AKTS opened at $20.90 on Tuesday. Aktis Oncology has a 52 week low of $18.52 and a 52 week high of $29.16.

Insiders Place Their Bets

In other Aktis Oncology news, major shareholder Vida Ventures Ii, Llc purchased 835,000 shares of the stock in a transaction dated Monday, January 12th. The stock was bought at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the acquisition, the insider owned 5,671,825 shares of the company’s stock, valued at approximately $102,092,850. This represents a 17.26% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Helen Susan Kim acquired 835,000 shares of Aktis Oncology stock in a transaction that occurred on Monday, January 12th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the purchase, the director directly owned 5,671,825 shares of the company’s stock, valued at $102,092,850. This represents a 17.26% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 6,117,776 shares of company stock valued at $110,119,968 over the last three months.

Trending Headlines about Aktis Oncology

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: Several major firms initiated coverage with bullish ratings and high price targets — Bank of America (Buy, $34 PT), Leerink Partners (Outperform, $31 PT), and JPMorgan (Overweight, $30 PT) — implying 43–63% upside vs. the current price, giving institutional validation to AKTS’s strategy and growth potential.
• Positive Sentiment: TD Cowen started coverage with a Buy, highlighting Aktis’s differentiated miniprotein radiopharma platform and projecting multi‑billion dollar sales potential; this initiation is also covered in TipRanks commentary. AKTS initiated with bullish view at TD Cowen — The Fly TipRanks coverage
• Positive Sentiment: Leerink and JPMorgan notes are summarized in market wire coverage, reinforcing the consensus bullish view from new analysts. Leerink/JPMorgan coverage — Benzinga
• Neutral Sentiment: Short-interest reports for early February show “0 shares” and NaN changes — likely data errors or reporting anomalies; current filings do not provide reliable evidence of elevated short pressure or a squeeze scenario.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.